Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Maleck V Vasseur; Michel Laurentie; Jean-Guy Rolland; Agnès Perrin-Guyomard; Jérôme Henri; Aude A Ferran; Pierre-Louis Toutain; Alain Bousquet-Mélou

Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Maleck V Vasseur Michel Laurentie ¹ Jean-Guy Rolland ¹ Agnès Perrin-Guyomard ¹ Jérôme Henri ¹ Aude A Ferran ² Pierre-Louis Toutain ² Alain Bousquet-Mélou ^{2, *}

* Corresponding author

1 ANSES - ANSES - Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail

2 Physiologie et Toxicologie Expérimentales

Abstract : The combination of efficacious treatment against bacterial infections and mitigation of antibiotic resistance amplification in gut microbiota is a major challenge for antimicrobial therapy in food-producing animals. In rats, we evaluated the impact of cefquinome, a fourth-generation cephalosporin, on both Klebsiella pneumoniae lung infection and intestinal flora harboring CTX-M-producing Enterobacteriaceae. Germfree rats received a fecal flora specimen from specific-pathogen-free pigs, to which a CTX-M-producing Escherichia coli strain had been added. K. pneumoniae cells were inoculated in the lungs of these gnotobiotic rats by using either a low (10(5) CFU) or a high (10(9) CFU) inoculum. Without treatment, all animals infected with the low or high K. pneumoniae inoculum developed pneumonia and died before 120 h postchallenge. In the treated groups, the low-inoculum rats received a 4-day treatment of 5 mg/kg of body weight cefquinome beginning at 24 h postchallenge (prepatent phase of the disease), and the high-inoculum rats received a 4-day treatment of 50 mg/kg cefquinome beginning when the animals expressed clinical signs of infection (patent phase of the disease). The dose of 50 mg/kg targeting the high K. pneumoniae inoculum cured all the treated rats and resulted in a massive amplification of CTX-M-producing Enterobacteriaceae. A dose of 5 mg/kg targeting the low K. pneumoniae inoculum cured all the rats and averted an outbreak of clinical disease, all without any amplification of CTX-M-producing Enterobacteriaceae. These findings might have implications for the development of new antimicrobial treatment strategies that ensure a cure for bacterial infections while avoiding the amplification of resistance genes of human concern in the gut microbiota of food-producing animals.

Mots-clés : cefquinome klebsiella pneumoniae résistance antibiotique antibiotic resistance flore feces fecal flora

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Pharmaceutical sciences / Medication

Complete list of metadatas

https://hal-anses.archives-ouvertes.fr/hal-00978511
Contributor : Emmanuelle Chiffoleau <>
Submitted on : Monday, April 14, 2014 - 12:09:51 PM
Last modification on : Friday, June 14, 2019 - 6:21:09 PM

Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Links full text

Identifiers

Collections

Citation

Export

Metrics

138

Contact

Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Links full text

Identifiers

Collections

Citation

Export

Share

Metrics

138

Contact